References
- Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344–347.
- Choy EH, Isenberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology (Oxford). 2002;41:7–13.
- Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet. 1999;353:1762–1763.
- Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993;94:379–387.
- Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993–2000.
- Hirakata M, Nagai S. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol. 2000;12:501–508.
- Marie I, Hachulla E, Chérin P, Dominique S, Hatron PY, Hellot MF et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthr Rheum. 2002;47:614–622.
- Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity. 2005;38:383–392.
- Pereira RM, Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine. 2011;78:41–44.
- Minetto MA, Lanfranco F, Motta G, Allasia S, Arvat E, D’Antona G. Steroid myopathy: some unresolved issues. J Endocrinol Invest. 2011;34:370–375.
- Ioannou Y, Sultan S, Isenberg DA. Myositis overlap syndromes. Curr Opin Rheumatol. 1999;11:468–474.
- Simmons PS, Miles JM, Gerich JE, Haymond MW. Increased proteolysis: an effect of increases in plasma cortisol within the physiologic range. J Clin Invest. 1984;73:412–420.
- Beaufrere B, Horber FF, Schwenk WF, Marsh HM, Matthews D, Gerich JE et al. Glucocorticosteroids increase leucine oxidation and impair leucine balance in humans. Am J Physiol. 1989;257:E712–E721.
- Ponyi A, Borgulya G, Constantin T, Váncsa A, Gergely L, Dankó K. Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology (Oxford). 2005;44:83–88.
- Sultan SM, Ioannou Y, Moss K, Isenberg DA. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford). 2002;41:22–26.
- Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoid-induced myopathy. J Endocrinol. 2008;197:1–10.
- Kanda F, Takatani K, Okuda S, Matsushita T, Chihara K. Preventive effects of insulin like growth factor-I on steroid-induced muscle atrophy. Muscle Nerve. 1999;22:213–217.
- LaPier TK. Glucocorticoid-induced muscle atrophy. The role of exercise in treatment and prevention. J Cardiopulm Rehabil. 1997;17:76–84.
- Löfberg E, Gutierrez A, Wernerman J, Anderstam B, Mitch WE, Price SR et al. Effects of high doses of glucocorticoids on free amino acids, ribosomes and protein turnover in human muscle. Eur J Clin Invest. 2002;32:345–353.
- Shah OJ, Anthony JC, Kimball SR, Jefferson LS. 4E-BP1 and S6K1: translational integration sites for nutritional and hormonal information in muscle. Am J Physiol Endocrinol Metab. 2000;279(4): E715–E729.
- Shimizu N, Yoshikawa N, Ito N, Maruyama T, Suzuki Y, Takeda S et al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab. 2011;13:170–182.
- Yamamoto D, Maki T, Herningtyas EH, Ikeshita N, Shibahara H, Sugiyama Y et al. Branched-chain amino acids protect against dexamethasone-induced soleus muscle atrophy in rats. Muscle Nerve. 2010;41:819–827.